The efficacy of melphalan/melphalan for injection

Injectable melphalan/melphalan (Melphalan flufenamide), as a new drug for the treatment of multiple myeloma, has shown good efficacy. In a major study involving 157 patients with multiple myeloma, injectable melphalan, combined with dexamethasone, effectively cleared the cancer and significantly slowed disease progression. The study results showed that the disease response of these patients stopped after three treatments, and some patients did not relapse after receiving treatment.

Specific data showed that among 52 patients whether they had not undergone transplantation or those who had completed transplantation, their disease progression improved after 3 years. Of this group of patients, approximately 29% had a positive response to the injectable melphalan and dexamethasone combination, as evidenced by a significant reduction in cancer-related signs, and this response lasted approximately 7.6 months. This result provides an important basis for the clinical application of melphalan for injection.

Separately, another study compared the effects of injectable melphalan in combination with dexamethasone to pomalidomide plus dexamethasone. The study subjects were mainly patients who had received treatment in the past but whose disease still progressed. The results showed that the average survival time of patients in the melphalan and dexamethasone group was 9.3 months, while the average survival time of the patients in the pomalidomide and dexamethasone group was only 4.6 months. This difference suggests that injectable melphalan has a significant advantage in extending patient survival.

Overall, the combination of melphalan for injection and dexamethasone resulted in an overall survival of 23.6 months, compared with 19.8 months for the pomalidomide and dexamethasone group. This result not only demonstrates the potential of injectable melphalan in the treatment of multiple myeloma, but also provides a valuable reference for clinicians when selecting the best treatment option. Therefore, as a new anti-cancer drug, the clinical application prospects of melphalan for injection are worth looking forward to.